Compound Detail
CHEMBL4284807
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
Basic Information
| ChEMBL ID | CHEMBL4284807 |
| Phase | Preclinical |
| Structure Type | MOL |
| InChI Key | ZTOFWUQDDVVMNS-UHFFFAOYSA-N |
2
Targets
2
Activities
1
Assay Types
0
PK Parameters
4
Publications
0
Known Names
Molecular Properties
480.8
MW (Da)
8.85
ALogP
4
HBA
0
HBD
33.2
PSA (Ų)
0.15
QED
1
Ro5 Violations
16
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| Availability | Unknown |
| Chirality | Unknown |
Activity Summary
EC50 2 meas. best 7.66
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Unchecked CHEMBL612545 | EC50 | 7.66 | 7.66 | 22.0 | 1 |
| Lymphocyte CHEMBL5314318 | EC50 | 7.6 | 7.6 | 25.0 | 1 |
Activity Data Samples
Top measurements by pChEMBL value
| Target | Type | Rel. | Value | Units | pChEMBL | Assay | PubMed |
|---|---|---|---|---|---|---|---|
| Unchecked | EC50 | = | 22.0 | nM | 7.66 | Inhibition of erastin-induced cell death in FRDA patient-derived fibroblast asse... | 33214825 |
| Lymphocyte | EC50 | = | 25.0 | nM | 7.6 | Anti-ferroptotic activity in FRDA patient-derived Lymphocyte assessed as reducti... | 33214825 |
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 30288223 | 10.1039/C8MD00274F | GM15850 | 21 |
| 30288223 | 10.1039/C8MD00274F | GM16216 | 20 |
| 33214825 | 10.1021/acsmedchemlett.0c00293 | Unchecked | 4 |
| 33214825 | 10.1021/acsmedchemlett.0c00293 | Lymphocyte | 2 |
Data from ChEMBL 36 via Core Engine